Literature DB >> 21120722

Advances in the diagnosis and management of central venous access device infections in children.

Asha Bowen1, Jonathan Carapetis.   

Abstract

Infection is a well-known complication of central venous access device (CVAD) use, with an incidence of 3-6 bloodstream infections per 1,000 catheter days in children. Prevention of CVAD infections has improved with new strategies including the use of chlorhexidine antisepsis, bundles, maximal sterile barriers for insertion, prophylactic locks, antibiotic impregnated catheters and tunnelling of long-term devices. Despite these strategies, catheter-related bloodstream infections (CRBSIs) continue to be an important health problem. New approaches to diagnosis include differential time to positivity and quantification of blood cultures and molecular diagnostics. The management of CRBSIs includes techniques for line salvage including ethanol, antibiotic, hydrochloric acid, taurolidine and urokinase locks. When these fail, line removal and antimicrobial therapy are recommended.

Entities:  

Mesh:

Year:  2011        PMID: 21120722     DOI: 10.1007/978-1-4419-7185-2_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Injection of gadolinium contrast through pediatric central venous catheters: a safety study.

Authors:  John M Moriarty; Geoffrey L Kung; Yanerys Ramos; Abbas N Moghaddam; Daniel B Ennis; J Paul Finn
Journal:  Pediatr Radiol       Date:  2012-04-24

2.  High positive predictive value of Gram stain on catheter-drawn blood samples for the diagnosis of catheter-related bloodstream infection in intensive care neonates.

Authors:  M Deleers; M Dodémont; B Van Overmeire; Y Hennequin; D Vermeylen; S Roisin; O Denis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-10       Impact factor: 3.267

3.  Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy.

Authors:  Elisa K McCarthy; Michelle T Ogawa; Rachel K Hopper; Jeffrey A Feinstein; Hayley A Gans
Journal:  Pulm Circ       Date:  2018-01-08       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.